Accessibility Menu
BioArctic Ab (publ) logo

BioArctic Ab (publ)(OTC) BRCTF

Market Cap$3.02BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2022)+29%
5 YearN/A
1 Year+2%
1 Month+7%
$36.92
+8.44%
+2.87Today
BioArctic Ab (publ) last closing stock price
MetricPriceDate
Last closeUSD 34.052026-09-02
BioArctic Ab (publ) stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+7.14%USD 31.782026-08-26
1 month+7.14%USD 31.782026-07-31
3 month-2.71%USD 35.002026-06-02
Year to date-1.44%USD 34.552025-12-30
1 year+1.51%USD 33.542025-09-02
3 year+26.07%USD 27.012023-07-24
Since inception+29.22%USD 26.352022-11-29

BioArctic Ab (publ) Financials at a Glance

Market Cap

$3.02BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

SEK 999.91M

Net Income (TTM)

SEK 105.64M

EPS (TTM)

$0.13

P/E Ratio

252.04

Dividend

$0.21

Beta (Volatility)

0.00 (Low)

Price

$36.92

Volume

100

Open

$36.92

Previous Close

$36.92

Daily Range

$36.92 - $36.92

52-Week Range

$27.82 - $40.00

Estimated Earnings Date

Nov 25, 2026

BRCTF News

Medical personnel preparing an injection.

What Are the Clinical Development Phases?

Benjamin LockeAug 16, 2025

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About BioArctic Ab (publ)

BioArctic AB (publ) is a biotechnology company focused on developing innovative biological drugs for patients with central nervous system disorders. The company specializes in addressing high unmet medical needs, particularly in neurodegenerative diseases such as Alzheimer's and Parkinson's. BioArctic is advancing several therapeutic monoclonal antibodies through various stages of clinical trials.

Products and Services
  • Development of lecanemab, currently in phase 3 clinical trials
  • Research collaboration agreements with Eisai and AbbVie
  • Innovative monoclonal antibodies targeting CNS disorders
Growth Outlook
  • Strong pipeline with multiple candidates in clinical and preclinical stages
  • Recent partnerships enhance research capabilities and market reach
  • Increasing demand for effective treatments in neurodegenerative diseases
Financial Highlights
  • Recent quarterly revenue of 245.4 million SEK, showing growth potential
  • Cash and short-term investments total 1.97 billion SEK, indicating strong liquidity
  • Net income for Q1 was 212.4 million SEK, reflecting operational strength
BioArctic AB (publ) is positioned in a critical sector of biotechnology, focusing on significant health challenges. The company's robust pipeline and strategic collaborations with established partners like Eisai and AbbVie provide a solid foundation for future growth. Recent financial performance indicates a strong liquidity position, which is essential for ongoing research and development efforts. The increasing prevalence of neurodegenerative diseases further underscores the potential market for BioArctic's innovative therapies.
AI Generated • Aug 29, 2026

Industry

Biotechnology

Sector

Health Care

Employees

150

CEO

Gunilla Christina Osswald, PhD

Website

www.bioarctic.se

Headquarters

Stockholm, AB 112 51, SE

BRCTF Financials

Key Financial Metrics (TTM)

Gross Margin

93.17%

Operating Margin

21.37%

Net Income Margin

10.53%

Return on Equity

5.18%

Return on Capital

68.02%

Return on Assets

3.74%

Earnings Yield

0.40%

Dividend Yield

0.63%

Payout Ratio

0.00%

Stock Overview

Market Cap

$3.02BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

88.72M

Volume

100

Avg. Volume

22.234

Financials (TTM)

Gross Profit

SEK 931.61M

Operating Income

SEK 214.20M

EBITDA

SEK 220.95M

Operating Cash Flow

SEK 242.01M

Capital Expenditure

-SEK 449.20M

Free Cash Flow

SEK 106.14M

Cash & ST Invst.

SEK 1.97B

Total Debt

SEK 89.83M

BioArctic Ab (publ) Performance Analysis

BioArctic Ab (publ) annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31SEK 22,558,637736.7%
20232023-12-31SEK 58,025,457157.2%
20242024-12-31SEK 24,341,109-58.1%
20252025-12-31SEK 203,834,737737.4%
BioArctic Ab (publ) sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-66.0%
Q42025-12-3137.7%
Q12026-03-31138.4%
Q22026-06-30-43.9%
BioArctic Ab (publ) annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31SEK -0.01-92.1%
20232023-12-31SEK 0.24N/A
20242024-12-31SEK -0.19N/A
20252025-12-31SEK 1.18N/A
BioArctic Ab (publ) sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-189.9%
Q42025-12-3189.8%
Q12026-03-312499.6%
Q22026-06-30-105.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

SEK 245.41M

-37.4%

Gross Profit

SEK 223.90M

-39.8%

Gross Margin

91.24%

N/A

Market Cap

$3.02BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$23.06M

N/A

Employees

131

N/A

Net Income

-SEK 11.07M

-111.5%

EBITDA

-SEK 2.48M

-101.3%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

SEK 1.97B

+3.0%

Total Debt

SEK 89.83M

+83.4%

Accounts Receivable

SEK 0.00

N/A

Inventory

SEK 0.00

N/A

Long Term Debt

SEK 72.50M

+109.8%

Short Term Debt

SEK 17.33M

+8.7%

Return on Assets

3.74%

N/A

Return on Invested Capital

9.97%

N/A

Free Cash Flow

SEK 0.00

-100.0%

Operating Cash Flow

SEK 136.66M

-88.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MEOBFMesoblast Limited
$1.90+0.00%
ONTTFOxford Nanopore Technologies plc
$2.40+12.15%
GENSFGenus plc
$31.07+0.00%
HTSUFHisamitsu Pharmaceutical Co., Inc.
$29.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$9.77-0.01%
HPEHewlett Packard Enterprise
$54.44+0.05%
FFord Motor Company
$14.41+0.02%
SNAPSnap
$5.70+0.02%

Questions About BRCTF

What is the current price of BioArctic Ab (publ)?

BioArctic Ab (publ) is trading at $36.92 per share.

What is the 52-week range for BioArctic Ab (publ)?

Over the past 52 weeks, BioArctic Ab (publ) has traded between $27.82 and $40.00.

How much debt does BioArctic Ab (publ) have?

As of the most recent reporting period, BioArctic Ab (publ) reported total debt of SEK 9.36M.

How much cash does BioArctic Ab (publ) have on hand?

BioArctic Ab (publ) reported SEK 111.73M in cash and cash equivalents in its most recent financial results.

What is BioArctic Ab (publ)’s dividend yield?

BioArctic Ab (publ) currently has a dividend yield of 0.63%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services